Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
Shilpa
S
Sayana
Paul
P
Prosser
Juan Carlos
JC
Ricaurte
Susan
S
Sanchez
Gerald
G
Hamwi
Jeanne
J
Hershey-Weber
Catherine
C
Chien
Anne
A
Easley
Thai
T
Nguyen
Lisha
L
Wilson
Homayoon
H
Khanlou
D000328:Adult; D004334:Drug Administration Schedule; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage* / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000627:therapeutic use; D011788:Quality of Life; D000068898:Raltegravir Potassium; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors; D010446:Peptide Fragments; D011760:Pyrrolidinones; D000077560:Enfuvirtide; D000068898:Raltegravir Potassium